Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.

Scrip Five Must Know Things
audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 April 2024, including: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca PLC looks to multiple cancer modalities; and an interview with Astellas Pharma, Inc.’s chief strategy officer.

This and all our other podcasts are available on the Citeline channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "The Shifting Sands Of Biopharma R&D" - Scrip, 8 April, 2024.)

(Also see "Big Pharma Oncology Strategies Aim To Treat Cancer Earlier" - Scrip, 9 April, 2024.)

(Also see "Semaglutide Might Treat Heart Failure Directly" - Scrip, 8 April, 2024.)

(Also see "AstraZeneca Looks To Many Modalities In Cancer" - Scrip, 8 April, 2024.)

(Also see "Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs" - Scrip, 8 April, 2024.)

Citeline · Scrip's Five Must-Know Things - 15 April 2024

Open Media

More from R&D

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Replimune CRL Could Hold Warning For Accelerated Approvals

 

FDA issued a complete response letter to Replimune’s BLA for a novel oncolytic immunotherapy for melanoma in a surprise to management and investors.

More from Scrip

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By 

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place

 

Regenxbio and Solid Biosciences believe they have a next-generation approach to AAV-based gene therapies – but must distance themselves from Sarepta’s safety and efficacy problems.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

 
• By 

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.